1. Home
  2. MYI vs FTRE Comparison

MYI vs FTRE Comparison

Compare MYI & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniYield Quality Fund III Inc

MYI

Blackrock MuniYield Quality Fund III Inc

HOLD

Current Price

$10.91

Market Cap

736.5M

Sector

Finance

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$12.74

Market Cap

864.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYI
FTRE
Founded
1992
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
736.5M
864.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MYI
FTRE
Price
$10.91
$12.74
Analyst Decision
Hold
Analyst Count
0
8
Target Price
N/A
$11.64
AVG Volume (30 Days)
256.7K
1.4M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
4.81%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,759,900,000.00
Revenue This Year
N/A
$0.47
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.88
52 Week Low
$9.32
$3.97
52 Week High
$11.70
$25.05

Technical Indicators

Market Signals
Indicator
MYI
FTRE
Relative Strength Index (RSI) 44.14 64.16
Support Level $10.83 $9.87
Resistance Level $10.95 $13.24
Average True Range (ATR) 0.08 0.86
MACD -0.01 0.20
Stochastic Oscillator 27.59 86.21

Price Performance

Historical Comparison
MYI
FTRE

About MYI Blackrock MuniYield Quality Fund III Inc

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: